279 related articles for article (PubMed ID: 33781112)
1. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
Chern A; Dagi Glass LR; Gudis DA
Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab for the treatment of thyroid eye disease.
Ju Y; Yang J
Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
Ali F; Chorsiya A; Anjum V; Ali A
Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
[TBL] [Abstract][Full Text] [Related]
6. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
Smith TJ
J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
9. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab: First Approval.
Markham A
Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
[TBL] [Abstract][Full Text] [Related]
13. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
14. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
Ding AS; Mahoney NR; Campbell AA; Creighton FX
Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity and Teprotumumab.
Highland J; Gordon S; Reddy D; Patel N
Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
[TBL] [Abstract][Full Text] [Related]
16. [Teprotumumab for thyroid-associated ophthalmopathy : OPTIC].
Gärtner R; Nitschmann S
Internist (Berl); 2020 Nov; 61(11):1208-1210. PubMed ID: 33025123
[No Abstract] [Full Text] [Related]
17. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
Smith TJ
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.
Douglas RS
Eye (Lond); 2019 Feb; 33(2):183-190. PubMed ID: 30575804
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
Chow A; Silkiss RZ
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
[TBL] [Abstract][Full Text] [Related]
20. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
